Analyses  ||| S:0 E:9 ||| NNS
of  ||| S:9 E:12 ||| IN
similarities  ||| S:12 E:25 ||| NNS
and  ||| S:25 E:29 ||| CC
differences  ||| S:29 E:41 ||| NNS
in  ||| S:41 E:44 ||| IN
glucocorticoid  ||| S:44 E:59 ||| JJ
therapy  ||| S:59 E:67 ||| NN
between  ||| S:67 E:75 ||| IN
rheumatoid  ||| S:75 E:86 ||| JJ
arthritis  ||| S:86 E:96 ||| NN
and  ||| S:96 E:100 ||| CC
ankylosing  ||| S:100 E:111 ||| JJ
spondylitis  ||| S:111 E:123 ||| NN
-  ||| S:123 E:125 ||| :
a  ||| S:125 E:127 ||| DT
systematic  ||| S:127 E:138 ||| JJ
comparison  ||| S:138 E:149 ||| NN
Glucocorticoids  ||| S:149 E:165 ||| NNP
( ||| S:165 E:166 ||| -LRB-
GCs ||| S:166 E:169 ||| NNP
)  ||| S:169 E:171 ||| -RRB-
have  ||| S:171 E:176 ||| VBP
powerful  ||| S:176 E:185 ||| JJ
and  ||| S:185 E:189 ||| CC
potent  ||| S:189 E:196 ||| JJ
anti-inflammatory  ||| S:196 E:214 ||| JJ
and  ||| S:214 E:218 ||| CC
immunomodulatory  ||| S:218 E:235 ||| JJ
effects  ||| S:235 E:243 ||| NNS
and  ||| S:243 E:247 ||| CC
are  ||| S:247 E:251 ||| VBP
widely  ||| S:251 E:258 ||| RB
established  ||| S:258 E:270 ||| VBN
in  ||| S:270 E:273 ||| IN
regard  ||| S:273 E:280 ||| NN
to  ||| S:280 E:283 ||| TO
the  ||| S:283 E:287 ||| DT
treatment  ||| S:287 E:297 ||| NN
of  ||| S:297 E:300 ||| IN
rheumatism  ||| S:300 E:311 ||| NN
and  ||| S:311 E:315 ||| CC
other  ||| S:315 E:321 ||| JJ
diseases ||| S:321 E:329 ||| NNS
.  ||| S:329 E:331 ||| .
In  ||| S:331 E:334 ||| IN
rheumatoid  ||| S:334 E:345 ||| JJ
arthritis  ||| S:345 E:355 ||| NN
( ||| S:355 E:356 ||| -LRB-
RA ||| S:356 E:358 ||| NNP
) ||| S:358 E:359 ||| -RRB-
,  ||| S:359 E:361 ||| ,
GCs  ||| S:361 E:365 ||| NNS
are  ||| S:365 E:369 ||| VBP
used  ||| S:369 E:374 ||| VBN
systemically  ||| S:374 E:387 ||| VBN
at  ||| S:387 E:390 ||| IN
several  ||| S:390 E:398 ||| JJ
different  ||| S:398 E:408 ||| JJ
dosages  ||| S:408 E:416 ||| NN
and ||| S:416 E:419 ||| CC
/ ||| S:419 E:420 ||| NNP
or  ||| S:420 E:423 ||| CC
local  ||| S:423 E:429 ||| JJ
( ||| S:429 E:430 ||| -LRB-
intraarticular ||| S:430 E:444 ||| LS
)  ||| S:444 E:446 ||| -RRB-
therapy ||| S:446 E:453 ||| NN
.  ||| S:453 E:455 ||| .
They  ||| S:455 E:460 ||| PRP
have  ||| S:460 E:465 ||| VBP
been  ||| S:465 E:470 ||| VBN
shown  ||| S:470 E:476 ||| VBN
to  ||| S:476 E:479 ||| TO
exert  ||| S:479 E:485 ||| VB
strong  ||| S:485 E:492 ||| JJ
short-term  ||| S:492 E:503 ||| JJ
anti-inflammatory  ||| S:503 E:521 ||| JJ
effects  ||| S:521 E:529 ||| NNS
but  ||| S:529 E:533 ||| CC
also  ||| S:533 E:538 ||| RB
long-term  ||| S:538 E:548 ||| JJ
positive  ||| S:548 E:557 ||| JJ
effects  ||| S:557 E:565 ||| NNS
on  ||| S:565 E:568 ||| IN
radiographic  ||| S:568 E:581 ||| JJ
progression  ||| S:581 E:593 ||| NN
of  ||| S:593 E:596 ||| IN
the  ||| S:596 E:600 ||| DT
disease ||| S:600 E:607 ||| NN
.  ||| S:607 E:609 ||| .
In  ||| S:609 E:612 ||| IN
comparison ||| S:612 E:622 ||| NN
,  ||| S:622 E:624 ||| ,
patients  ||| S:624 E:633 ||| NNS
with  ||| S:633 E:638 ||| IN
ankylosing  ||| S:638 E:649 ||| JJ
spondylitis  ||| S:649 E:661 ||| NNS
( ||| S:661 E:662 ||| -LRB-
AS ||| S:662 E:664 ||| NNP
)  ||| S:664 E:666 ||| -RRB-
are  ||| S:666 E:670 ||| VBP
considered  ||| S:670 E:681 ||| VBN
to  ||| S:681 E:684 ||| TO
be  ||| S:684 E:687 ||| VB
less  ||| S:687 E:692 ||| RBR
responsive  ||| S:692 E:703 ||| JJ
to  ||| S:703 E:706 ||| TO
GC  ||| S:706 E:709 ||| NNP
therapy  ||| S:709 E:717 ||| NN
than  ||| S:717 E:722 ||| IN
patients  ||| S:722 E:731 ||| NNS
with  ||| S:731 E:736 ||| IN
RA ||| S:736 E:738 ||| NNP
,  ||| S:738 E:740 ||| ,
although  ||| S:740 E:749 ||| IN
controlled  ||| S:749 E:760 ||| JJ
studies  ||| S:760 E:768 ||| NNS
on  ||| S:768 E:771 ||| IN
the  ||| S:771 E:775 ||| DT
effects  ||| S:775 E:783 ||| NNS
of  ||| S:783 E:786 ||| IN
low-dose  ||| S:786 E:795 ||| JJ
GCs  ||| S:795 E:799 ||| NN
in  ||| S:799 E:802 ||| IN
AS  ||| S:802 E:805 ||| NNP
are  ||| S:805 E:809 ||| VBP
lacking ||| S:809 E:816 ||| VBG
.  ||| S:816 E:818 ||| .
In  ||| S:818 E:821 ||| IN
AS ||| S:821 E:823 ||| NNP
,  ||| S:823 E:825 ||| ,
GCs  ||| S:825 E:829 ||| NNS
are  ||| S:829 E:833 ||| VBP
mainly  ||| S:833 E:840 ||| RB
used  ||| S:840 E:845 ||| VBN
for  ||| S:845 E:849 ||| IN
local  ||| S:849 E:855 ||| JJ
therapy  ||| S:855 E:863 ||| NN
and  ||| S:863 E:867 ||| CC
occasionally  ||| S:867 E:880 ||| RB
for  ||| S:880 E:884 ||| IN
systemic  ||| S:884 E:893 ||| JJ
pulse  ||| S:893 E:899 ||| NN
therapy  ||| S:899 E:907 ||| NN
only ||| S:907 E:911 ||| RB
.  ||| S:911 E:913 ||| .
The  ||| S:913 E:917 ||| DT
underlying  ||| S:917 E:928 ||| JJ
mechanisms  ||| S:928 E:939 ||| NNS
for  ||| S:939 E:943 ||| IN
these  ||| S:943 E:949 ||| DT
differences  ||| S:949 E:961 ||| NNS
are  ||| S:961 E:965 ||| VBP
unclear ||| S:965 E:972 ||| JJ
.  ||| S:972 E:974 ||| .
GCs  ||| S:974 E:978 ||| JJ
act  ||| S:978 E:982 ||| NN
on  ||| S:982 E:985 ||| IN
primary  ||| S:985 E:993 ||| JJ
and  ||| S:993 E:997 ||| CC
secondary  ||| S:997 E:1007 ||| JJ
immune  ||| S:1007 E:1014 ||| JJ
cells  ||| S:1014 E:1020 ||| NNS
via  ||| S:1020 E:1024 ||| IN
different  ||| S:1024 E:1034 ||| JJ
mechanisms  ||| S:1034 E:1045 ||| NNS
of  ||| S:1045 E:1048 ||| IN
action ||| S:1048 E:1054 ||| NN
:  ||| S:1054 E:1056 ||| :
cytosolic  ||| S:1056 E:1066 ||| FW
GC  ||| S:1066 E:1069 ||| FW
receptor  ||| S:1069 E:1078 ||| FW
( ||| S:1078 E:1079 ||| -LRB-
cGCR ||| S:1079 E:1083 ||| NNP
) ||| S:1083 E:1084 ||| -RRB-
-mediated  ||| S:1084 E:1094 ||| JJ
genomic  ||| S:1094 E:1102 ||| NN
and  ||| S:1102 E:1106 ||| CC
non-genomic  ||| S:1106 E:1118 ||| JJ
effects ||| S:1118 E:1125 ||| NNS
,  ||| S:1125 E:1127 ||| ,
membrane-bound  ||| S:1127 E:1142 ||| NNP
GC  ||| S:1142 E:1145 ||| NNP
receptor  ||| S:1145 E:1154 ||| NN
( ||| S:1154 E:1155 ||| -LRB-
mGCR ||| S:1155 E:1159 ||| NNP
) ||| S:1159 E:1160 ||| -RRB-
-mediated  ||| S:1160 E:1170 ||| JJ
non-genomic  ||| S:1170 E:1182 ||| JJ
effects  ||| S:1182 E:1190 ||| NNS
and  ||| S:1190 E:1194 ||| CC
-  ||| S:1194 E:1196 ||| :
as  ||| S:1196 E:1199 ||| RB
achieved  ||| S:1199 E:1208 ||| VBN
at  ||| S:1208 E:1211 ||| IN
very  ||| S:1211 E:1216 ||| RB
high  ||| S:1216 E:1221 ||| JJ
concentrations  ||| S:1221 E:1236 ||| NNS
-  ||| S:1236 E:1238 ||| :
non-specific  ||| S:1238 E:1251 ||| JJ
non-genomic  ||| S:1251 E:1263 ||| JJ
effects ||| S:1263 E:1270 ||| NNS
.  ||| S:1270 E:1272 ||| .
The  ||| S:1272 E:1276 ||| DT
phenomenon  ||| S:1276 E:1287 ||| NN
of  ||| S:1287 E:1290 ||| IN
GC  ||| S:1290 E:1293 ||| NNP
resistance  ||| S:1293 E:1304 ||| NN
is  ||| S:1304 E:1307 ||| VBZ
also  ||| S:1307 E:1312 ||| RB
known  ||| S:1312 E:1318 ||| VBN
in  ||| S:1318 E:1321 ||| IN
RA ||| S:1321 E:1323 ||| NNP
.  ||| S:1323 E:1325 ||| .
Several  ||| S:1325 E:1333 ||| JJ
different  ||| S:1333 E:1343 ||| JJ
mechanisms  ||| S:1343 E:1354 ||| NNS
may  ||| S:1354 E:1358 ||| MD
mediate  ||| S:1358 E:1366 ||| VB
this  ||| S:1366 E:1371 ||| DT
phenomenon ||| S:1371 E:1381 ||| NN
;  ||| S:1381 E:1383 ||| :
among  ||| S:1383 E:1389 ||| IN
them  ||| S:1389 E:1394 ||| PRP
are  ||| S:1394 E:1398 ||| VBP
alterations  ||| S:1398 E:1410 ||| VBN
in  ||| S:1410 E:1413 ||| IN
number ||| S:1413 E:1419 ||| NN
,  ||| S:1419 E:1421 ||| ,
binding  ||| S:1421 E:1429 ||| JJ
affinity  ||| S:1429 E:1438 ||| NN
or  ||| S:1438 E:1441 ||| CC
phosphorylation  ||| S:1441 E:1457 ||| JJ
status  ||| S:1457 E:1464 ||| NN
of  ||| S:1464 E:1467 ||| IN
the  ||| S:1467 E:1471 ||| DT
GCR ||| S:1471 E:1474 ||| NNP
,  ||| S:1474 E:1476 ||| ,
polymorphic  ||| S:1476 E:1488 ||| JJ
changes  ||| S:1488 E:1496 ||| NNS
and ||| S:1496 E:1499 ||| CC
/ ||| S:1499 E:1500 ||| NNP
or  ||| S:1500 E:1503 ||| CC
over-expression  ||| S:1503 E:1519 ||| JJ
of  ||| S:1519 E:1522 ||| IN
chaperones ||| S:1522 E:1532 ||| JJ
/  ||| S:1532 E:1534 ||| NNP
co-chaperones ||| S:1534 E:1547 ||| NNP
,  ||| S:1547 E:1549 ||| ,
increased  ||| S:1549 E:1559 ||| VBN
expression  ||| S:1559 E:1570 ||| NN
of  ||| S:1570 E:1573 ||| IN
inflammatory  ||| S:1573 E:1586 ||| JJ
transcription  ||| S:1586 E:1600 ||| JJ
factors ||| S:1600 E:1607 ||| NNS
,  ||| S:1607 E:1609 ||| ,
the  ||| S:1609 E:1613 ||| DT
multidrug  ||| S:1613 E:1623 ||| JJ
resistance  ||| S:1623 E:1634 ||| NN
pump ||| S:1634 E:1638 ||| NN
,  ||| S:1638 E:1640 ||| ,
over-expression  ||| S:1640 E:1656 ||| JJ
of  ||| S:1656 E:1659 ||| IN
the  ||| S:1659 E:1663 ||| DT
GCR  ||| S:1663 E:1667 ||| NNP
beta  ||| S:1667 E:1672 ||| NN
isoform ||| S:1672 E:1679 ||| NN
,  ||| S:1679 E:1681 ||| ,
alteration  ||| S:1681 E:1692 ||| VBG
in  ||| S:1692 E:1695 ||| IN
the  ||| S:1695 E:1699 ||| DT
expression  ||| S:1699 E:1710 ||| NN
of  ||| S:1710 E:1713 ||| IN
mGCR  ||| S:1713 E:1718 ||| JJ
and  ||| S:1718 E:1722 ||| CC
imbalance  ||| S:1722 E:1732 ||| NN
of  ||| S:1732 E:1735 ||| IN
11beta-hydroxysteroid  ||| S:1735 E:1757 ||| CD
dehydrogenase  ||| S:1757 E:1771 ||| JJ
type  ||| S:1771 E:1776 ||| NN
1  ||| S:1776 E:1778 ||| CD
&  ||| S:1778 E:1780 ||| CC
2  ||| S:1780 E:1782 ||| CD
activity ||| S:1782 E:1790 ||| NN
.  ||| S:1790 E:1792 ||| .
Translation  ||| S:1792 E:1804 ||| NN
of  ||| S:1804 E:1807 ||| IN
insights  ||| S:1807 E:1816 ||| NNS
on  ||| S:1816 E:1819 ||| IN
GC  ||| S:1819 E:1822 ||| NNP
action  ||| S:1822 E:1829 ||| NN
and  ||| S:1829 E:1833 ||| CC
resistance  ||| S:1833 E:1844 ||| NN
obtained  ||| S:1844 E:1853 ||| VBN
in  ||| S:1853 E:1856 ||| IN
RA  ||| S:1856 E:1859 ||| NNP
to  ||| S:1859 E:1862 ||| TO
AS  ||| S:1862 E:1865 ||| NNP
may  ||| S:1865 E:1869 ||| MD
contribute  ||| S:1869 E:1880 ||| VB
to  ||| S:1880 E:1883 ||| TO
a  ||| S:1883 E:1885 ||| DT
better  ||| S:1885 E:1892 ||| JJR
understanding  ||| S:1892 E:1906 ||| NN
of  ||| S:1906 E:1909 ||| IN
the  ||| S:1909 E:1913 ||| DT
pathophysiology  ||| S:1913 E:1929 ||| NN
of  ||| S:1929 E:1932 ||| IN
both  ||| S:1932 E:1937 ||| DT
diseases ||| S:1937 E:1945 ||| NNS
.  ||| S:1945 E:1947 ||| .
